Citations

Clear

6274 citation(s) found for "To, Andrew".

Carotid Artery Angioplasty and Stenting: 2-Dimensional Operative Video
Darwal, Maureen A, Liebman, Kenneth, Binning, Mandy J., Bain, Mark, Bendock, Bernard, Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levy, Elad, Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , Schirmer, Clemens M , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, E, Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan Samuel

Mayo Clinic

Operative Neurosurgery | August 12, 2021 | Volume: 19 | Issue: 6 | Pages: E595-E596

10.1093/ons/opaa275 | PMID 34383932 Get It

Abstract Carotid artery angioplasty and stenting (CAS) has been shown to be equally effective as carotid endarterectomy (CEA) for carotid stenosis in both symptomatic and asymptomatic disease. 1 In patients who are considered high risk for endarterectomy, CAS is safe and effective. 2 While this is a common procedure, proper technique is crucial to ensure that the procedure is safe with minimal risk of stroke. This patient consented to treatment. The following is a video detailing the CAS procedure in a 77-yr-old male with a symptomatic 65% carotid stenosis (by NASCET criteria 3 ) in a patient with prior CEA.
Endovascular Coil Embolization of a Posterior Communicating Artery Aneurysm: 2-Dimensional Operative Video
Darwal, Maureen A, Hakma, Zakaria, Binning, Mandy J., Bain, Mark, Bendock, Bernard, Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond, Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Schirmer, Clemens M , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | August 12, 2021 | Volume: 19 | Issue: 6 | Pages: E597-E598

10.1093/ons/opaa278 | PMID 34383933 Get It

Abstract Since the International Subarachnoid Aneurysm Trial, 1 endovascular treatment has been the favored treatment for appropriate ruptured intracranial aneurysms. While our endovascular technology has advanced to allow us to treat the majority of intracranial aneurysms, simple coil embolization is still the most common modality. This video demonstrates the fundamentals of aneurysm catheterization and coiling for safe treatment. In addition, the set-up and devices are detailed. This video is to add to the library of basic techniques that will aid a large number of practitioners. This patient consented to endovascular treatment. The video demonstrates endovascular coil embolization of a posterior communicating artery aneurysm in a 76-yr-old female who presented with a subarachnoid hemorrhage. Image of biplane suite in video used courtesy of Siemens Medical Solutions USA, Inc. Illustration at 5:12 reprinted from Yasargil MG, et al, Microneurosurgery IV B , p. 9, Thieme, New York, 1995.
Prospective evaluation of high‐dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function
Barreto, Jason N. , Thompson, Carrie A. , Mara, Kristin C. , Rule, Andrew D. , Kashani, Kianoush , Leung, Nelson , Larson, Thomas R. , McGovern, Renee M., Witzig, Thomas E. , Frazee, Erin N. , Reid, Joel M. , Thompson, Carrie A , Mara, Kristin C , Rule, Andrew D , Kashani, Kianoush B , Leung, Nelson , Witzig, T.E.

Mayo Clinic

Clinical and Translational Science | August 11, 2021 | Volume: 15 | Issue: 1 | Pages: 105-117

10.1111/cts.13125 | PMID 34378331 Get It

AbstractHigh‐dose methotrexate (HDMTX) pharmacokinetics (PKs), including the best estimated glomerular filtration rate (eGFR) equation that reflects methotrexate (MTX) clearance, requires investigation. This prospective, observational, single‐center study evaluated adult patients with lymphoma treated with HDMTX. Samples were collected at predefined time points up to 96 h postinfusion. MTX and 7‐hydroxy‐MTX PKs were estimated by standard noncompartmental analysis. Linear regression determined which serum creatinine‐ or cystatin C‐based eGFR equation best predicted MTX clearance. The 80 included patients had a median (interquartile range [IQR]) age of 68.6 years (IQR 59.2–75.6), 54 (67.5%) were men, and 74 (92.5%) were White. The median (IQR) dose of MTX was 7.6 (IQR 4.8–11.3) grams. Median clearance was similar across three dosing levels at 4.5–5.6 L/h and was consistent with linear PKs. Liver function, weight, age, sex, concomitant chemotherapy, and number of previous MTX doses did not impact clearance. MTX area under the curve (AUC) values varied over a fourfold range and appeared to increase in proportion to the dose. The eGFRcys (ml/min) equation most closely correlated with MTX clearance in both the entire cohort and after excluding outlier MTX clearance values (r = 0.31 and 0.51, respectively). HDMTX as a 4‐h infusion displays high interpatient pharmacokinetic variability. Population PK modeling to optimize MTX AUC attainment requires further evaluation. The cystatin C‐based eGFR equation most closely estimated MTX clearance and should be investigated for dosing and monitoring in adults requiring MTX as part of lymphoma management.
Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia
Nandy, Sreyankar , Raphaely, Rebecca A., Muniappan, Ashok, Shih, Angela, Roop, Benjamin W., Sharma, Amita, Keyes, Colleen M., Colby, Thomas V., Auchincloss, Hugh G., Gaissert, Henning A., Lanuti, Michael, Morse, Christopher R., Ott, Harald C., Wain, John C., Wright, Cameron D., Garcia-Moliner, Maria L., Smith, Maxwell L., VanderLaan, Paul A., Berigei, Sarita R., Mino-Kenudson, Mari, Horick, Nora K., Liang, Lloyd L., Davies, Diane L., Szabari, Margit V., Caravan, Peter, Medoff, Benjamin D., Tager, Andrew M., Suter, Melissa J., Hariri, Lida P., Horick, Nora , Liang, Lloyd L. , VanderLaan, Paul A. , Shih, Angela , Nandy, Sreyankar , Raphaely, Rebecca A., Muniappan, Ashok, Roop, Benjamin W., Sharma, Amita, Keyes, Colleen M., Colby, Thomas V., Auchincloss, Hugh G., Gaissert, Henning A., Lanuti, Michael, Morse, Christopher R., Ott, Harald C., Wain, John C., Wright, Cameron D., Garcia-Moliner, Maria L., Smith, Maxwell L., Berigei, Sarita R., Mino-Kenudson, Mari, Liang, Lloyd L., Davies, Diane L., Szabari, Margit V., Caravan, Peter, Medoff, Benjamin D., Tager, Andrew M., Suter, Melissa J., Hariri, Lida P., Shih, Angela , Horick, Nora

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 10, 2021 | Volume: 204 | Issue: 10 | Pages: 1164-1179

10.1164/rccm.202104-0847oc | PMID 34375171 Get It

Abstract Rationale Early, accurate diagnosis of interstitial lung disease (ILD) informs prognosis and therapy, especially in idiopathic pulmonary fibrosis (IPF). Current diagnostic methods are imperfect. High-resolution computed tomography has limited resolution, and surgical lung biopsy (SLB) carries risks of morbidity and mortality. Endobronchial optical coherence tomography (EB-OCT) is a low-risk, bronchoscope-compatible modality that images large lung volumes in vivo with microscopic resolution, including subpleural lung, and has the potential to improve the diagnostic accuracy of bronchoscopy for ILD diagnosis. Objectives We performed a prospective diagnostic accuracy study of EB-OCT in patients with ILD with a low-confidence diagnosis undergoing SLB. The primary endpoints were EB-OCT sensitivity/specificity for diagnosis of the histopathologic pattern of usual interstitial pneumonia (UIP) and clinical IPF. The secondary endpoint was agreement between EB-OCT and SLB for diagnosis of the ILD fibrosis pattern. Methods EB-OCT was performed immediately before SLB. The resulting EB-OCT images and histopathology were interpreted by blinded, independent pathologists. Clinical diagnosis was obtained from the treating pulmonologists after SLB, blinded to EB-OCT. Measurements and Main Results We enrolled 31 patients, and 4 were excluded because of inconclusive histopathology or lack of EB-OCT data. Twenty-seven patients were included in the analysis (16 men, average age: 65.0 yr): 12 were diagnosed with UIP and 15 with non-UIP ILD. Average FVC and Dl CO were 75.3% (SD, 18.5) and 53.5% (SD, 16.4), respectively. Sensitivity and specificity of EB-OCT was 100% (95% confidence interval, 75.8–100.0%) and 100% (79.6–100%), respectively, for both histopathologic UIP and clinical diagnosis of IPF. There was high agreement between EB-OCT and histopathology for diagnosis of ILD fibrosis pattern (weighted κ: 0.87 [0.72–1.0]). Conclusions EB-OCT is a safe, accurate method for microscopic ILD diagnosis, as a complement to high-resolution computed tomography and an alternative to SLB.
Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high‐risk myelodysplastic syndromes: Challenges and opportunities in implementation
Warlick, Erica D. , Üstün, Celalettin , Andreescu, Astrid C. M., Bonagura, Anthony, Brunner, Andrew M. , Foran, James M. , Kindwall‐Keller, Tamila L. , Klimek, Virginia M., Pease, Daniel F. , Waldman, Bryce, Horowitz, Mary M. , Burns, Linda J. , Khera, Nandita , Foran, James M , Khera, Nandita , Chandra, Abhinav Binod , Juckett, Mark , Steensma, David P.

Mayo Clinic

Cancer | August 10, 2021 | Volume: 127 | Issue: 23 | Pages: 4339-4347

10.1002/cncr.33826 | PMID 34375439 Get It

Lay Summary People who have advanced myelodysplastic syndromes (MDS) may live longer if they get a bone marrow transplant (BMT) instead of other therapies. However, only 15% of people with MDS actually get BMT. Experts say community physicians and transplant physicians should team up with insurance companies and patient advocacy groups to 1) spread this news about lifesaving advances in BMT, 2) ensure that everyone can afford health care, 3) provide emotional support for patients and families, 4) help patients and families get transportation and housing if they need to travel for transplant, and 5) improve care for people of under‐represented racial and ethnic backgrounds.
Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older
Munshi, Pashna N. , Vesole, David H. , Martin, Andrew St., Dávila, Omar, Kumar, Shaji , Qazilbash, Muzaffar H. , Shah, Nina , D’Souza, Anita , Qazilbash, Muzaffar H , D'Souza, Anita , Hari, Parameswaran

Mayo Clinic

Cancer | August 10, 2021 | Volume: 127 | Issue: 22 | Pages: 4233-4239

10.1002/cncr.33831 | PMID 34374445 Get It

BackgroundConsolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used for patients with multiple myeloma (MM). We studied AHCT use and outcomes in patients with MM ≥75 years old.MethodsPatients with MM ≥75 years old receiving AHCT between 2013 and 2017 in the United States were identified using the Center for International Blood and Marrow Transplant Research database. Relapse and/or progression (REL), progression‐free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models. Covariates used were age, sex, Karnofsky performance score (KPS), HCT‐comorbidity index (HCT‐CI), International Staging System and/or Durie‐Salmon stage, high‐risk cytogenetics, melphalan dose, and disease status at and 1 year after transplant. AHCT utilization rate using the Surveillance, Epidemiology, and End Results database was used to estimate specific incidence among ≥75 years old by race and gender.ResultsOf 360 patients, 63% were male, 84% were White, 56% had KPS <90, and 57% had HCT‐CI ≥3. The 100‐day transplant‐related mortality was 1% (0%‐2%) with a 2‐year REL rate of 27% (95% confidence interval [CI], 22%‐33%), PFS of 66% (95% CI, 60%‐72%), and OS of 83% (95% CI, 78%‐87%). On multivariate analysis, only high‐risk cytogenetics was associated with REL risk and decreased PFS. In White males, transplant utilization rate was 5.2%‐5.8% compared to 3.5%‐4.0% in African American males (P = .02). There was 3.37‐3.79% transplant utilization in White females compared to 1.88‐2.12% in African American females (P < .01).ConclusionsThe use of AHCT was associated with excellent 2‐year outcomes in this selected MM population ≥75 years old. Transplant utilization for patients ≥75 years old remains low with significant racial and gender disparities.
Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)
Snyder, Rebecca A. , Le‐Rademacher, Jennifer , Dodge, Andrew , Chang, George J. , Innocenti, Federico , Blanke, Charles D. , Lenz, Heinz‐Josef, Polite, Blasé N. , Le-Rademacher, Jennifer G , Zemla, Tyler J, Polite, Blasé N , He, Jun , Ou, Fang‐Shu , Zemla, Tyler , Paskett, Electra D. , Lenz, Heinz‐Josef , Venook, Alan P. , Snyder, Rebecca A

Mayo Clinic

Cancer | August 10, 2021 | Volume: 127 | Issue: 20 | Pages: 3801-3808

10.1002/cncr.33649 | PMID 34374082 Get It

BackgroundThe objective of this study was to evaluate the association between self‐identified race and overall survival (OS), progression‐free survival (PFS), and response to therapy among patients enrolled in the randomized Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial.MethodsPatients with advanced or metastatic colorectal cancer who were enrolled in the CALGB/SWOG 80405 trial were identified by race. On the basis of covariates (treatment arm, KRAS status, sex, age, and body mass index), each Black patient was exact matched with a White patient. The association between race and OS and PFS was examined using a marginal Cox proportional hazard model for matched pairs. The interaction between KRAS status and race was tested in the model. The association between race and response to therapy and adverse events were examined using a marginal logistic regression model.ResultsIn total, 392 patients were matched and included in the final data set. No difference in OS (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.73‐1.16), PFS (HR, 0.97; 95% CI, 0.78‐1.20), or response to therapy (odds ratio [OR], 1.00; 95% CI, 0.65‐1.52) was observed between Black and White patients. Patients with KRAS mutant status (HR, 1.31; 95% CI, 1.02‐1.67), a performance statusscore of 1 (reference, a performance status of 0; HR, 1.49; 95% CI, 1.18‐1.88), or ≥3 metastatic sites (reference, 1 metastatic site; HR, 1.67; 95% CI, 1.22‐2.28) experienced worse OS. Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24‐0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72‐1.65).ConclusionsNo difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial.Lay Summary Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer. The purpose of this study was to determine whether there was a difference in cancer‐specific outcomes among Black and White patients receiving equivalent treatment on the CALGB/SWOG 80405 randomized clinical trial. In this study, there was no difference in overall survival, progression‐free survival, or response to therapy between Black and White patients treated on a clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.
Assessment of Opioid Use and Analgesic Requirements After Endoscopic Sinus Surgery
Ayoub, Noel , Raviv, Joseph, Thamboo, Andrew , Chowdhury, Naweed I. , Stokken, Janalee K., O’Brien, Erin K. , Shah, Sharan , Akbar, Nadeem , Roozdar, Pooya, Patel, Zara M. , Hwang, Peter H. , O'Brien, Erin K , Patel, Zara , Hwang, Peter H , Choby, Garret , Turner, Justin H. , Abuzeid, Waleed M. , Ma, Yifei , Chandra, Rakesh K. , Nayak, Jayakar V.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 5, 2021 | Volume: 147 | Issue: 9 | Pages: 811

10.1001/jamaoto.2021.1839 | PMID 34351376 Get It

COVLIAS 1.0: Lung Segmentation in COVID-19 Computed Tomography Scans Using Hybrid Deep Learning Artificial Intelligence Models
Suri, Jasjit S. , Agarwal, Sushant , Ketireddy, Vedmanvitha, Columbu, Marta, Saba, Luca , Gupta, Suneet Kumar , Singh, Inder M. , Turk, Monika, Chadha, Paramjit S., Johri, Amer M. , Khanna, Narendra N. , Višković, Klaudija , Laird, John R. , Pareek, Gyan , Miner, Martin , Sobel, David , Balestrieri, Antonella , Sfikakis, Petros P. , Tsoulfas, George, Protogerou, Athanase D. , Misra, Durga Prasanna , Agarwal, Vikas , Teji, Jagjit S. , Al-Maini, Mustafa , Dhanjil, Surinder, Nicolaides, Andrew , Rathore, Vijay , Fatemi, Mostafa , Krishnan, Pudukode R., Frence, Nagy, Naidu, Subbaram, Nagy, F. , Tsoulfas, George , Protogerou, Athanasios , Misra, Durga Prasanna , Agarwal, Vikas , Nicolaides, Andrew , Alizad, Azra , Fatemi, Mostafa , Ferenc, Nagy , Agarwal, Sushant , Suri, Jasjit S. , Pathak, Rajesh, Faa, Gavino , Mavrogeni, Sophie , Kitas, George D. , Sharma, Aditya , Alizad, Azra , Frence, Nagy, Ruzsa, Zoltán , Gupta, Archna , Kalra, Mannudeep K.

Mayo Clinic

Diagnostics | August 4, 2021 | Volume: 11 | Issue: 8 | Pages: 1405

10.3390/diagnostics11081405 | PMID 34441340 Get It

Background: COVID-19 lung segmentation using Computed Tomography (CT) scans is important for the diagnosis of lung severity. The process of automated lung segmentation is challenging due to (a) CT radiation dosage and (b) ground-glass opacities caused by COVID-19. The lung segmentation methodologies proposed in 2020 were semi- or automated but not reliable, accurate, and user-friendly. The proposed study presents a COVID Lung Image Analysis System (COVLIAS 1.0, AtheroPoint™, Roseville, CA, USA) consisting of hybrid deep learning (HDL) models for lung segmentation. Methodology: The COVLIAS 1.0 consists of three methods based on solo deep learning (SDL) or hybrid deep learning (HDL). SegNet is proposed in the SDL category while VGG-SegNet and ResNet-SegNet are designed under the HDL paradigm. The three proposed AI approaches were benchmarked against the National Institute of Health (NIH)-based conventional segmentation model using fuzzy-connectedness. A cross-validation protocol with a 40:60 ratio between training and testing was designed, with 10% validation data. The ground truth (GT) was manually traced by a radiologist trained personnel. For performance evaluation, nine different criteria were selected to perform the evaluation of SDL or HDL lung segmentation regions and lungs long axis against GT. Results: Using the database of 5000 chest CT images (from 72 patients), COVLIAS 1.0 yielded AUC of ~0.96, ~0.97, ~0.98, and ~0.96 (p-value < 0.001), respectively within 5% range of GT area, for SegNet, VGG-SegNet, ResNet-SegNet, and NIH. The mean Figure of Merit using four models (left and right lung) was above 94%. On benchmarking against the National Institute of Health (NIH) segmentation method, the proposed model demonstrated a 58% and 44% improvement in ResNet-SegNet, 52% and 36% improvement in VGG-SegNet for lung area, and lung long axis, respectively. The PE statistics performance was in the following order: ResNet-SegNet > VGG-SegNet > NIH > SegNet. The HDL runs in <1 s on test data per image. Conclusions: The COVLIAS 1.0 system can be applied in real-time for radiology-based clinical settings.
NCCN Guidelines® Insights: Palliative Care, Version 2.2021
Dans, Maria, Kutner, Jean S. , Agarwal, Rajiv , Baker, Justin N. , Bauman, Jessica R. , Carey, Elise C. , Dalal, Shalini , Doberman, Danielle J. , Fecher, Leslie A. , Kapo, Jennifer, Lee, Richard T. , McCammon, Susan , Mitchell, William M. , Ogunseitan, Adeboye, Portman, Diane , Ramchandran, Kavitha , Sutton, Linda , Teply, Melissa , Terauchi, Stephanie , Walling, Anne M. , Zachariah, Finly , Bergman, Mary Anne, Ogba, Ndiya , Campbell, Mallory, Agarwal, Rajiv , Ramchandran, Kavitha J , Beck, Anna Catherine , Campbell, Toby C. , Case, Amy Allen , Epstein, Andrew S , Jones, Joshua , Loggers, Elizabeth T , Mitchell, William, Temel, Jennifer S. , Thomas, Jane deLima

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 780-788

10.6004/jnccn.2021.0033 | PMID 34340208 Get It

Palliative care has evolved to be an integral part of comprehensive cancer care with the goal of early intervention to improve quality of life and patient outcomes. The NCCN Guidelines for Palliative Care provide recommendations to help the primary oncology team promote the best quality of life possible throughout the illness trajectory for each patient with cancer. The NCCN Palliative Care Panel meets annually to evaluate and update recommendations based on panel members’ clinical expertise and emerging scientific data. These NCCN Guidelines Insights summarize the panel’s recent discussions and highlights updates on the importance of fostering adaptive coping strategies for patients and families, and on the role of pharmacologic and nonpharmacologic interventions to optimize symptom management.